This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
by Zacks Equity Research
CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -250% and 66.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Kamada (KMDA) Q1 Earnings Match Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of 0% and 5.28%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 0% and 96.97%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
by Sundeep Ganoria
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.
Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab
by Zacks Equity Research
MRNA intends to use the funds to support the development of its mRNA-based bird flu shot and expand clinical studies for additional subtypes of pandemic influenza.
Vaccine Stocks Jump After CDC Reports First US Bird-Flu Death
by Sundeep Ganoria
The first bird-flu fatality in the United States sparks investor interest in several vaccine makers that are developing experimental H5N1 vaccines.
Is the Options Market Predicting a Spike in CureVac (CVAC) Stock?
by Zacks Equity Research
Investors need to pay close attention to CureVac (CVAC) stock based on the movements in the options market lately.
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
by Zacks Equity Research
The phase I/II proof-of-concept study evaluating GSK's herpes simplex virus vaccine candidate, GSK3943104, fails to meet the primary efficacy objective.
CorMedix (CRMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 3.85% and 7.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adherex Technologies (FENC) delivered earnings and revenue surprises of -433.33% and 46.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -9.76% and 24.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Ontrak, Inc. (OTRK) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ontrak (OTRK) delivered earnings and revenue surprises of -90% and 5.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
CureVac N.V. (CVAC) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
CureVac (CVAC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte (INCY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of -333.33% and 2.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
CureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
CureVac (CVAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
by Zacks Equity Research
GSK revamps its existing collaboration deal with partner CureVac, converting it from a collaboration deal into a licensing agreement related to mRNA vaccine candidates for COVID-19 and influenza.
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
by Zacks Equity Research
GSK and CureVac (CVAC) are in the spotlight following a restructuring of their vaccine agreement.
Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine
by Zacks Equity Research
Moderna (MRNA) expects this funding to help support the development of its mRNA-based pre-pandemic vaccine against the H5 influenza virus, which is responsible for causing avian influenza or bird flu.
Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)
by Zacks Equity Research
CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -15.09% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)
by Zacks Equity Research
The heavy selling pressure might have exhausted for CureVac N.V. (CVAC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Can CureVac N.V. (CVAC) Climb 191.74% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 191.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Company News for Jan 11, 2023
by Zacks Equity Research
Companies In The News Are: SNX, ACI, MSFT, CVAC.
Wall Street Analysts Believe CureVac N.V. (CVAC) Could Rally 139%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 139% upside potential for CureVac N.V. (CVAC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bet on These 4 Biotech Stocks With Bright Prospects
by Ekta Bagri
New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.